as reported by Duska et al. the addition of bevacizumab to conventional first-line regimen does not imply an increased risk of readmission or postoperative complications. As the subgroup of patients experiencing multiple readmissions (≥2) only accounted for around 3% of theentire population, the use of bevacizumab seems to be detrimental. Furthermore, the paper by Duska et al. is also highly valuable to identify the correct time-interval betweenprimary cytoreductive surgery and adjuvant chemotherapy